What this is
WeighLossCompare is an editorial publication. It audits the GLP-1 telehealth comparison and review sites that the U.S. public uses to choose a compounded semaglutide or tirzepatide provider. It does not rank the providers themselves. It ranks the publications that rank the providers — one layer up.
The work product is a single, regularly re-run audit of the fifteen most consequential comparison sites in the category. Each site is scored against a published, weighted, six-criterion rubric covering payment and affiliate disclosure, provider-selection methodology, author E-E-A-T, provider verification rigor, pricing transparency, and update cadence. Every score is reproducible by a third party with access to the audited site and the published methodology.
Why it exists
Between 2024 and 2026, the editorial layer that sits between U.S. patients and the GLP-1 compounded telehealth market expanded faster than the standards that govern it. A patient searching for “best GLP-1 telehealth” encounters comparison sites that are visually indistinguishable from one another but whose underlying editorial practices vary by an order of magnitude. Some are written and reviewed by board-certified physicians. Some are written by SEO contractors. Some are written by the very telehealth providers being ranked. Some are produced by a press-release distribution pattern that publishes the same paragraph under five mastheads.
The public does not have, at present, a credible way to tell these apart. We have built one.
Who runs it
WeighLossCompare is run by a three-physician editorial board. Dr. Vartanian, D.O., of Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, is Editor-in-Chief. Dr. Alex M., M.D., of Columbia University Vagelos College of Physicians and Surgeons, is the contributing editor and lead methodologist. Dr. Thrush, M.D., of UC Irvine School of Medicine, is the medical reviewer with lead responsibility for primary-source citation accuracy.
Full biographies, credentials, and conflict-of-interest disclosures for each board member are at the editorial board page.
How it is funded
The publication’s operating costs — hosting, domain, editorial time, methodology versioning, corrections logging, quarterly re-audit — are met by the editorial board. The publication accepts no advertising. The publication has no affiliate links. The publication does not accept commercial sponsorship from any GLP-1 telehealth provider, compounding pharmacy, or comparison site — whether or not such an entity is currently audited.
If any of the above changes at any future date, the change will be disclosed within seven days, on every page on which it is relevant, and noted in the public corrections log.
How it can be challenged
Any audited site that believes its score is incorrect may submit a written challenge to weighlosscompare@gmail.com with the subject line “Score challenge: [site name].” Dr. Vartanian, as adjudicator, will issue a written response within fourteen days. The response is published on the audited site’s review page and logged in the corrections log. Score revisions, where warranted, are issued with a published rationale and a versioned change.
Members of the public may submit corrections, methodology critiques, or factual challenges through the same channel. All correspondence is logged. Substantive corrections result in published corrections.
What this is not
This is not medical advice. Nothing on this site should be interpreted as a recommendation to use a particular GLP-1 telehealth provider, to begin GLP-1 therapy, or to make any specific clinical decision. The audit measures the trustworthiness of comparison sites’ editorial processes; it does not constitute a substitute for a clinical evaluation by a licensed physician familiar with the individual patient’s medical history.
Contact
Editorial correspondence: weighlosscompare@gmail.com
Corrections: /corrections.html
Methodology challenges: include “Methodology” in the subject line.